{{위키데이터 속성 추적}}
{{소문자}}
{{약 정보
| Verifiedfields = 
| verifiedrevid = 
| drug_name  = rVSV-ZEBOV 백신
| INN               = 
| image = Ebola virus em.png
| width             = 
| alt               = 
| caption = 에볼라 바이러스의 전자현미경 모습

<!-- Vaccine data -->
| type = vaccine
| target = 에볼라 바이러스
| vaccine_type = 재조합

<!-- Clinical data -->
| pronounce         =
| tradename         = Ervebo
| Drugs.com         = {{drugs.com|ppa|ebola-zaire-vaccine-live}}
| MedlinePlus       = 
| licence_CA        = <!-- Health Canada may use generic or brand name (generic name preferred) -->
| licence_EU        = yes
| DailyMedID        = <!-- DailyMed may use generic or brand name (generic name preferred) -->
| licence_US        = <!-- FDA may use generic or brand name (generic name preferred) -->
| pregnancy_AU      = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_AU_comment = 
| pregnancy_US      = <!-- A / B / C / D / X / N -->
| pregnancy_US_comment = 
| pregnancy_category = 
| dependency_liability = 
| addiction_liability =
| routes_of_administration = Intramuscular
| class             = 
| ATCvet            = 
| ATC_prefix        = None <!-- scheduled to be J07BX02 in 2021 -->
| ATC_suffix        = 
| ATC_supplemental  = 

<!-- Legal status -->
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_AU_comment = 
| legal_BR =  <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F-->
| legal_BR_comment = 
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_CA_comment = 
| legal_DE = <!-- Anlage I, II, III or Unscheduled-->
| legal_DE_comment = 
| legal_NZ = <!-- Class A, B, C -->
| legal_NZ_comment = 
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->
| legal_UK_comment = 
| legal_US = Rx-only
| legal_US_comment = 
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV-->
| legal_UN_comment = 
| legal_status      = Rx-only

<!-- Pharmacokinetic data -->
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| metabolites       = 
| onset             = 
| elimination_half-life = 
| duration_of_action = 
| excretion         = 

<!-- Identifiers -->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number        = 
| CAS_supplemental  = 
| PubChem =  
| PubChemSubstance  = 
| IUPHAR_ligand     = 
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank          = DB15595
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID      = none
| UNII              = 
| KEGG              = 
| ChEBI             = 
| ChEMBL            = 
| NIAID_ChemDB      =
| PDB_ligand        = 
| synonyms          = V920<ref>{{저널 인용|vauthors=Monath TP, Fast PE, Modjarrad K, Clarke DK, Martin BK, Fusco J, Nichols R, Heppner DG, Simon JK, Dubey S, Troth SP, Wolf J, Singh V, Coller BA, Robertson JS | display-authors=3 |title=rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment |journal=Vaccine: X |date=April 2019 |volume=1 |at=100009 |doi=10.1016/j.jvacx.2019.100009|pmid=31384731 |pmc=6668225 |doi-access=free }}</ref>

<!-- Chemical and physical data -->
| IUPAC_name        = 
| chemical_formula  = 
| C= | H= | Ag= | Al= | As= | Au= | B= | Bi= | Br= | Ca= | Cl= | Co= | F= | Fe= | Gd= | I= 
| K= | Li= | Mg= | Mn= | N= | Na= | O= | P= | Pt= | S= | Sb= | Se= | Sr= | Tc= | Zn= | charge= 
| molecular_weight  = 
| SMILES            = 
| Jmol              = 
| StdInChI          = 
| StdInChI_comment  = 
| StdInChIKey       = 
| density           = 
| density_notes     = 
| melting_point     = 
| melting_high      = 
| melting_notes     = 
| boiling_point     = 
| boiling_notes     = 
| solubility        = 
| sol_units         = 
| specific_rotation = 
}}

'''재조합형 소낭성 구내염 바이러스-자이르 에볼라 바이러스'''('''rVSV-ZEBOV''') 통칭 '''에볼라 바이러스 생백신'''은 [[자이르에볼라바이러스]]로 발병하는 [[에볼라 출혈열]]을 예방할 수 있는 [[백신]]이다.<ref name="Ervebo FDA label">{{웹 인용| url=https://www.fda.gov/media/133748/download | format=PDF | title=Ervebo (Ebola Zaire Vaccine, Live) Suspension for intramuscular injection | publisher=Merck Sharp & Dohme }}</ref><ref name="Ervebo EPAR">{{웹 인용| title=Ervebo EPAR | website=[[European Medicines Agency]] (EMA) | date=16 October 2019 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/ervebo | access-date=29 March 2020}}</ref><ref>{{저널 인용|vauthors=Trad MA, Naughton W, Yeung A, Mazlin L, O'sullivan M, Gilroy N, Fisher DA, Stuart RL | display-authors=3 |title=Ebola virus disease: An update on current prevention and management strategies |journal=Journal of Clinical Virology |date=January 2017|volume=86|pages=5–13|pmid=27893999|doi=10.1016/j.jcv.2016.11.005|hdl=10144/618818 | hdl-access=free | doi-access=free }}</ref><ref>{{저널 인용||vauthors=Pavot V |title=Ebola virus vaccines: Where do we stand?|journal=Clinical Immunology|date=December 2016|volume=173|pages=44–49|doi=10.1016/j.clim.2016.10.016|pmid=27910805}}</ref> [[포위접종]]을 통해 rVSV-ZEBOV를 접종할 경우 높은 수준으로 에볼라 예방이 가능하다.<ref name=Medaglini2017/><ref name="ars-2019-04-16" /><ref name="WHO-12-april-2019" /> 백신을 접종받은 사람들의 절반은 두통, 피로, 근육통을 포함한 경미하거나 중간 정도의 부작용을 일으키는 것이 보고되어 있다.<ref name=Medaglini2017>{{저널 인용|last1=Medaglini|first1=D|last2=Siegrist|first2=CA|title=Immunomonitoring of human responses to the rVSV-ZEBOV Ebola vaccine.|journal=Current Opinion in Virology|date=April 2017|volume=23|pages=88–94|doi=10.1016/j.coviro.2017.03.008|pmid=28460340|doi-access=free}}</ref>

rVSV-ZEBOV는 [[재조합 DNA|재조합]]된 복제 가능형 백신이다.<ref name=JIDpaper>{{저널 인용|last=Marzi|first=Andrea |date= November 2011|title= Vesicular Stomatitis Virus–Based Ebola Vaccines With Improved Cross-Protective Efficacy|url= http://jid.oxfordjournals.org/content/204/suppl_3/S1066.full|journal= Journal of Infectious Diseases|volume=204 |issue=suppl 3 |pages=S1066–S1074 |doi=10.1093/infdis/jir348 |pmid=21987743 |access-date=July 31, 2015|display-authors=etal|pmc=3203393}}</ref> 외형은 [[인디애나 수포성바이러스]](VSV)로 에볼라바이러스에 대한 중화 [[면역 반응]]을 일으키기 위해 자이르 에볼라바이러스의 [[당단백질]]을 발현하도록 유전자 조작이 가해졌다.<ref name="Ervebo FDA label" />

rVSV-ZEBOV는 2019년 유럽연합과 미국에서 의료 승인을 허가받았다.<ref name="Ervebo EPAR" /><ref name="FDA PR">{{보도자료 인용| title=First FDA-approved vaccine for the prevention of Ebola virus disease, marking a critical milestone in public health preparedness and response | website=U.S. [[Food and Drug Administration]] (FDA) | date=19 December 2019 | url=https://www.fda.gov/news-events/press-announcements/first-fda-approved-vaccine-prevention-ebola-virus-disease-marking-critical-milestone-public-health | archive-url=https://web.archive.org/web/20191220052152/https://www.fda.gov/news-events/press-announcements/first-fda-approved-vaccine-prevention-ebola-virus-disease-marking-critical-milestone-public-health | archive-date=20 December 2019 | url-status=live | access-date=19 December 2019}}</ref><ref>{{웹 인용| title=Ervebo | website=U.S. [[Food and Drug Administration]] (FDA) | date=19 December 2019 | url=http://www.fda.gov/vaccines-blood-biologics/ervebo | access-date=28 March 2020 | id=STN: 125690 }}</ref> 이 백신은 캐나다 [[위니펙]]에 있는 [[캐나다 보건국]](PHAC) 산하 [[국립미생물연구소]](NML)에서 연구되었다.<ref name=NYT2014-Oct>{{뉴스 인용| title=Ebola Vaccine, Ready for Test, Sat on the Shelf | first=Denise | last=Grady | website=[[The New York Times]] | date=October 23, 2014 | url=https://www.nytimes.com/2014/10/24/health/without-lucrative-market-potential-ebola-vaccine-was-shelved-for-years.html | access-date=December 21, 2019}}</ref> 캐나다 보건국은 소규모 회사인 뉴링크 제네틱스(NewLink Genetics)에게 약물 개발권을 부여하였고 2014년 뉴링크는 [[MSD (기업)|MSD]]에 라이선스를 넘겼다.<ref name=GEN2014>{{뉴스 인용|title=Merck & Co. Licenses NewLink's Ebola Vaccine Candidate|url=http://www.genengnews.com/gen-news-highlights/merck-co-licenses-newlink-s-ebola-vaccine-candidate/81250631|work=Genetic Engineering & Biotechnology News|date=November 24, 2014|확인날짜=2020-04-01|보존url=https://web.archive.org/web/20180518055647/https://www.genengnews.com/gen-news-highlights/merck-co-licenses-newlink-s-ebola-vaccine-candidate/81250631|보존날짜=2018-05-18|url-status=dead}}</ref> 이 백신은 [[2018년 에카퇴르주 에볼라 유행]] 당시 [[콩고 민주 공화국]]에서 처음으로 사용하였으며,<ref>{{뉴스 인용|last1=McKenzie|first1=David|title=Fear and failure: How Ebola sparked a global health revolution|url=https://edition.cnn.com/2018/05/26/health/ebola-outbreaks-west-africa-congo-revolution-mckenzie-intl/index.html|access-date=May 26, 2018|publisher=[[CNN]]|date=May 26, 2018}}</ref> [[키부 에볼라 유행]] 시기부터 본격적으로 사용되어 9만명 이상의 사람들이 접종받았다.<ref name="WHO-12-april-2019" />

== 의료적 사용 ==
2016년 3월 가나에서 에볼라가 유행하기 시작하자 임시적으로 약 800명이 VSV-ZEBOV 예방접종을 받았다.<ref name="WHOguineaEmerg">{{웹 인용|url=https://www.who.int/en/news-room/feature-stories/detail/who-coordinating-vaccination-of-contacts-to-contain-ebola-flare-up-in-guinea |title=WHO coordinating vaccination of contacts to contain Ebola flare-up in Guinea|date=March 2016|website=[[World Health Organization]] (WHO)|access-date=May 14, 2016}}</ref> 2017년 [[2017년 콩고 민주 공화국 에볼라 유행|콩고 민주 공화국에서 에볼라가 유행]]하자 콩고 보건부는 백신의 긴급 사용을 허가했으나<ref>{{뉴스 인용| url=https://www.reuters.com/article/us-health-ebola-congo-idUSKBN18P0WN | title=Congo approves use of Ebola vaccination to fight outbreak | date=May 29, 2017 | work=Reuters | access-date=May 29, 2017}}</ref><ref name="naturevaccine">{{저널 인용|url=https://www.nature.com/news/ebola-vaccine-approved-for-use-in-ongoing-outbreak-1.22024|title=Ebola vaccine approved for use in ongoing outbreak |first=Amy|last=Maxmen |journal=Nature|doi=10.1038/nature.2017.22024|year=2017 }}</ref> 즉시 배포되지는 않았다.<ref>{{보고서 인용|title=Ebola Virus Disease Democratic Republic of the Congo: External Situation Report 22 |publisher=[[World Health Organization]] (WHO) Regional Office for Africa |date=June 2017 |hdl=10665/255645 |vauthors=((World Health Organization)), ((Regional Office for Africa)), ((Health Emergencies Programme)) | hdl-access=free }}</ref>

2019년 4월 콩고 민주 공화국에서 에볼라 바이러스가 유행하자 [[세계 보건 기구]]는 예비조사연구에서 포위접종을 할 시 rVSV-ZEBOV-GP 백신은 접종을 하지 않은 것과 비교하여 에볼라 전염을 막는 데 대략 97.5%의 효과를 보였다고 발표했다.<ref name="ars-2019-04-16">{{웹 인용|url=https://arstechnica.com/science/2019/04/ebola-vaccine-is-97-5-effective-early-outbreak-data-suggests/|title=As Ebola outbreak rages, vaccine is 97.5% effective, protecting over 90K people|last=Mole|first=Beth|date=2019-04-16|website=Ars Technica|access-date=2019-04-17}}</ref><ref name="WHO-12-april-2019">{{보고서 인용|url=https://www.who.int/csr/resources/publications/ebola/ebola-ring-vaccination-results-12-april-2019.pdf|title=Ebola Ring Vaccination Results April 12, 2019|last=|first=|date=April 12, 2019|website=[[World Health Organization]] (WHO)|archive-url=|archive-date=|access-date=April 17, 2019|lay-url=https://reliefweb.int/report/democratic-republic-congo/preliminary-results-efficacy-rvsv-zebov-gp-ebola-vaccine-using-ring }}</ref>

== 부작용 ==
전신 부작용에는 두통, 열, 피로, 관절통 및 근육통, 메스꺼움, 관절염, 발진, 비정상적인 발한 등이 있다.<ref name=Medaglini2017/><ref name=Martinez2015rev>{{저널 인용|vauthors=Martínez-Romero C, García-Sastre A | year = 2015 | title = Against the clock towards new Ebola virus therapies | url = | journal = Virus Res. | volume = 209| issue = | pages = 4–10| doi = 10.1016/j.virusres.2015.05.025 | pmid = 26057711 }}</ref><ref>{{저널 인용|vauthors=Shuchman M |title=Ebola vaccine trial in west Africa faces criticism |journal=Lancet |volume=385 |issue=9981 |pages=1933–4 |date=May 2015 |pmid=25979835 |doi=10.1016/S0140-6736(15)60938-2 }}</ref><ref name="Ervebo FDA label" /> 이 외에 주사한 부위에 통증, 붓기, 피부 발적(redness) 등이 나타날 수 있다.<ref name="Ervebo FDA label" />

== 생화학 ==
rVSV-ZEBOV는 약화한 [[재조합 DNA|재조합]] 인디애나 수포성바이러스 생백신으로 천연 외피 [[당단백질]](P03522)을 1995년 콩고 민주 공화국 [[키퀴트]]에서 채취한 자이르 에볼라바이러스의 유전자(P87666)로 대치한 형태이다.<ref name=Martinez2015rev/><ref name=Choi2015rev>{{저널 인용| author = Choi WY | date = January 2015 | title = Progress of vaccine and drug development for Ebola preparedness | url = | journal = Clin Exp Vaccine Res. | volume = 4 | issue = 1| pages = 11–16 | doi = 10.7774/cevr.2015.4.1.11 | pmid = 25648233 |pmc=4313103}}</ref><ref>{{저널 인용| author = Regules JA | date = April 2015 | title = A Recombinant Vesicular Stomatitis Virus Ebola Vaccine – Preliminary Report | journal = N Engl J Med | volume = 376| issue = 4| pages = 330–341| pmid = 25830322 | pmc = 5408576 | doi=10.1056/NEJMoa1414216|display-authors=etal}}</ref> 1상 시험용 백신은 IDT Biologika가 제조하였다.<ref>Hôpitaux Universitaires de Genève [http://www.hug-ge.ch/ebola-vaccine-candidate/faqs-vsv-zebov-vaccine-against-ebola-virus#22 FAQs about the context of this clinical trial: Question 22]</ref><ref name=strangestar>[https://www.thestar.com/news/canada/2014/11/25/the_strange_tale_of_canadas_ebola_vaccine_walkom.html The strange tale of Canada's ebola vaccine: Walkom. Commercial rights to a vaccine worth $50 million were sold to a U.S. middleman for $205,000.] By Thomas Walkom, The Star, November 25, 2014</ref> 3상 시험용 백신은 [[MSD (기업)|MSD]]가 [[베로 세포]]를 이용해 제조하였다.<ref>Carly Helfand for FierceVaccine. November 21, 2014 [http://www.fiercevaccines.com/story/bloomberg-newlink-merck-ebola-vaccine-production-talks/2014-11-21 NewLink, Merck sign Ebola vaccine licensing pact] {{웨이백|url=http://www.fiercevaccines.com/story/bloomberg-newlink-merck-ebola-vaccine-production-talks/2014-11-21 |date=20200630155156 }}</ref><ref>Zachary Brennan for BioPharma Reporter. November 25, 2014. [http://www.biopharma-reporter.com/Bio-Developments/Merck-to-manufacture-NewLink-Ebola-vaccine-in-house Merck to manufacture NewLink Ebola vaccine in-house]</ref>

== 같이 보기 ==
* [[cAd3-ZEBOV]]
* [[ZMapp]]
* [[에볼라 백신]]
* [[에볼라 유행 목록]]

== 각주 ==
{{각주}}

== 참고 문헌 ==
* {{웹 인용 | title=Scientists hail '100% effective' Ebola vaccine | website=[[National Health Service]] | location=England | date=August 3, 2015 | url=https://www.nhs.uk/news/medication/scientists-hail-100-effective-ebola-vaccine/ | 확인날짜=2020-04-01 | archive-date=2019-11-15 | archive-url=https://web.archive.org/web/20191115060333/https://www.nhs.uk/news/medication/scientists-hail-100-effective-ebola-vaccine/ | url-status=dead }}
* {{저널 인용|vauthors=Marzi A, Robertson SJ, Haddock E, Feldmann F, Hanley PW, Scott DP, Strong JE, Kobinger G, Best SM, Feldmann H |display-authors=3|title=VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain|journal=Science|date=August 14, 2015|volume=349|issue=6249|pages=739–42|doi=10.1126/science.aab3920|issn=0036-8075|pmid=26249231}}

== 외부 링크 ==
* {{MeSH 이름|Ebola Vaccines}}

[[분류:에볼라]]
[[분류:서아프리카 에볼라 유행]]
[[분류:바이러스 벡터 백신]]